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of acute G2 GU toxicity was about 3 times if the prostate 
volume is ≥ 80 cc (p -value 0.004; 95% CI: 1.05 - 9.5). In the 
adjusted prediction model using the logistic regression, the 
probability of acute G2 GU toxicity was about 60% with the 
same prostate volume cut-off (p-value 0.001; 95% CI: 0.13 - 
0.46), with an attitude to develop a moderate toxicity in the 
first 3 weeks from the beginning of treatment. In the late 
setting, a trend to significance (p=0.076) to develop an acute 
GU toxicity ≥ G1 was found for bladder V60 Gy ≥ 15%. 
 
Conclusion: In moderate hypofractionation in 30 fractions for 
prostate cancer, a prostate gland volume greater than 80 cc 
resulted as predictor of moderate acute GU toxicity. 
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Purpose or Objective: We have created and implemented in 
our department a new scheme of hypofractionated salvage 
volume modulated arc therapy with simultaneous integrated 
boost for patients with recurrence of prostate cancer (PCa) 
after radical prostatectomy (RP). The aims of our research 
are to evaluate toxicities and biochemical response rate. 
 
Material and Methods: Patients with recurrence of PCa after 
RP have been treated by hypofractionated (HF) salvage 
radiotherapy (SRT). Сharacteristics of HF radiotherapy were 
as follows: the prescribed dose to the regional lymphatic 
nodes was 46.8 Gy of 1.8 Gy per fraction, to the prostate bed 
- 61.1 Gy of 2.35 Gy per fraction in case of biochemical 
recurrence (BR) and if region of clinical recurrence (CR) was 
identified - 65 Gy of 2.5 Gy each, in 26 fractions with 
pretreatment imaging; VMAT (two arcs: CW (185°-175°), CCW 
(175°-185°) technology with SIB was used. Toxicities were 
scored using RTOG/EORTC Radiation Toxicity Grading. 
 
Results: 41 patients were treated by the HF SRT. Median 
follow-up was 22 months (10 - 30). Biochemical control rate – 
37 (90.2%) patients, locoregional control rate – 41 (100 %) 
patients. No grade 3 or greater acute toxicities were 
observed.  
 
Conclusion: We would like to suggest a new scheme of HF 
SRT with SIB in 26 fractions for patients with recurrence of 
PCa after RP. The toxicities and early biochemical response 
rates were comparable with conventional fractionation SRT.  
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Purpose or Objective: The Aim of this study is to evaluate 
PSA kinetics in men with intermediate and high risk prostate 
cancer treated with HDR brachytherapy boost in combination 
with external beam radiotherapy (EBRT) and short term 
androgen deprivation therapy (ADT). 
 
Material and Methods: Data from 134 consecutive patients 
treated with HDR brachytherapy boost in combination with 
external beam radiotherapy was extracted from a 
prospectively maintained database. All the patients had a 
minimum follow up of 4 years. Patients who were on 
androgen deprivation therapy for over 12 months were 
excluded from the analysis. After exclusion we had 95 
evaluable patients. All patients received either 17 Gy in 2 
fractions or 15 Gy in single fraction of HDR brachytherapy 
boost followed by external beam radiotherapy 37.5 Gy in 15 
fractions. 70% of patients received Androgen deprivation 
therapy (ADT) for less than or equal to 6 months, 15% 
received for 6- 12 months, and 15% received no hormones. 3-
6 months of ADT was given neoadjuvantly. Date of HDR boost 
was considered as time=0. Benign PSA bounce was defined as 
PSA rise of >0.2ng/ml followed by subsequent decline to pre 
bounce level. 
 
Results: Median follow-up was 4.3 years. At the time of 
median follow up the median PSA was 0.19. PSA bounce was 
seen in 32.6% (n=31). Magnitude of PSA bounce was <1ng/ml 
in 55% (n=17), 1-2ng/ml in 13% (n=4), >2ng/ml in 32% (N=10). 
In 16 out of 17 patients with a PSA bounce of <1ng/ml was 
due to a benign bounce. 50% of patients with a PSA bounce 
between 1-2ng/ml had a benign bounce and the remaining 
50% developed biochemical failure. In 9 out of 10 patients 
who had a PSA bounce of >2ng/ml subsequently developed a 
biochemical failure . Most common  
time for benign PSA bounce was between 6 and 18 months. 
 
 
 
Conclusion: PSA bounce is a common phenomenon which 
occurs in about a third of men who were treated with short 
term ADT in combination with HDR boost and EBRT. Benign 
PSA bounce tends to have a smaller magnitude of rise in PSA 
<1ng/ml. However patients who developed biochemical 
failure had PSA bounce of larger magnitude >2ng/ml. 
Investigators at the time of submission of the abstract are 
examining variables which predict PSA bounce. 
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Purpose or Objective: A retrospective analysis in 368 
consecutives organ confined prostate cancer (PC) patients 
has been made for evaluating the rates of haematuria, 
etiology and onset time. All these patients have been treated 
from September 2001 to December 2013 with different 
multimodality radical radiotherapy approaches: Intensity 
Guided Modulated radiotherapy (IGRT), Low dose rate 
brachytherapy (LDR BT) exclusively, LDR BT plus External 
radiotherapy (EBRT) or High dose rate Brachytherapy (HDR-
BT) plus EBRT. 
 
Material and Methods: Median age of the whole group was 
70,5 years (range 60-81y). Median PSA at diagnostic of the 
prostate cancer was 9.3 ng/ml (range 4,67-95 ng/ml). Median 
Gleason 6 (range 2-10). 20 patients (41,47%) had received 
IGRT radiotherapy treatment, 4 patients (8%) LDR BT, 10 
patients (21%) LDR plus EBRT and 14 patients (30%) HDR-BT 
plus EBRT. In 17 patients (35,4%) the complete pelvis (L5-S1) 
